Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.56 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4028302 | 0.98 | SLC6A1 (0.55) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL407286 | 0.89 | KMT2A (0.53) | TSHRKMT2ACYP2D6MCL1 | |
| Hydrochloric Acid SCHEMBL440964 | 0.88 | KMT2A (0.56) | KMT2ACYP2D6MCL1 | |
| Tert-Butyl Formate SCHEMBL27689725 | 0.85 | KMT2A (0.42) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Tert-Butyl Formate SCHEMBL27751802 | 0.85 | KMT2A (0.42) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2323451 | 0.83 | HSD11B1 (0.49) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL5583005 | 0.83 | KMT2A (0.51) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL4671412 | 0.83 | MGLL (0.49) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL7001156 | 0.83 | KMT2A (0.64) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL4777663 | 0.83 | MGLL (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112707857-A | Method for preparing piperidine compound by hydrogen transfer reduction of pyridine compound | 西南石油大学 | 2021-04-27 | — | — | CN | disclosed |
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | ARTAX BIOPHARMA INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | ARTAX BIOPHARMA INC. | 2020-04-30 | — | — | US | disclosed |
| WO-2018170078-A1 | ARYL-PIPERIDINE DERIVATIVES | ARTAX BIOPHARMA, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| EP-3375778-A1 | ARYL-PIPERIDINE DERIVATIVES | Artax Biopharma Inc. (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-2909170-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| WO-2014060341-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| EP-0983238-A4 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORP (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1082307-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING 2-SUBSTITUTED PIPERIDINE STEREOISOMERS | CELGENE CORPORATION (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-0983238-A1 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999061425-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING 2-SUBSTITUTED PIPERIDINE STEREOISOMERS | CELGENE CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5965734-A | REACTING 2-SUBSTITUTED PYRIDINE WITH HYDROGEN IN THE PRESENCE OF CATALYST AND ALKANOIC ACID, ADDING AKLYL ALKANOATE, AND THEN REACTING WITH AQUEOUS BASE THEN WITH ACID AND RESOLVING AGENT TO FORM ACID SALTS OF 1-ERYTHRO PIPERIDINE STEREOSIOMERS | CELGENE CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5936091-A | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1998052921-A1 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
| EP-0028473-A1 | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-05-13 | — | — | EP | disclosed |
| US-4101662-A | DISUBSTITUTED PIPERIDINES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-07-18 | — | — | US | disclosed |
| US-3968217-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | CD4, CD2, CCR1 | SLC6A1 4617/4885SLC6A11 4836/4885TSHR 1207/4885 |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | SLC6A1 357/4885SLC6A11 529/4885TSHR 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.